Janssen gets European Commission nod for AKEEGA to treat metastatic castration resistant prostate cancer with BRCA1/2 mutations
Beerse: The Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the European Commission (EC) has granted marketing authorisation for AKEEGA (niraparib and abiraterone acetate [AA]), in the form of a dual action tablet (DAT), given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline […] More